Dupixent is on track to deliver about €2 billion in annual sales, but Sanofi execs say they’re still in the early stages of the launch. The company is investing globally to support the rollout in atopic dermatitis, its original indication,
read moreAbbVie blockbuster-to-be Rinvoq only just hit the scene in rheumatoid arthritis, but it’s already on its way to a second indication. Thrusday, the Illinois drugmaker said its newcomer had hit its primary endpoint in a phase 3 psoriatic arthritis (PsA)
read moreTurns out, Novartis’ AveXis unit delayed another report about Zolgensma and its animal-testing data. AveXis has known since March about the safety signal that prompted the FDA to halt enrollment in a trial of Zolgensma as a spinal injection—but left
read moreBristol-Myers Squibb’s Eliquis has looked like a world-beater as it continues to rake in market share and keep a stranglehold on its anticoagulant rivals. But another Bristol blockbuster—I-O med Opdivo—hit something of a wall in the third quarter, and execs
read moreMerck and Gilead Sciences have been battling over hepatitis C drug patents for years, and at one point, Merck thought it had won—to the tune of a multibillion-dollar jury verdict. But Gilead managed to turn that win into a loss,
read moreThe pharma giant reported sales of £9.4 billion for the third quarter, with HIV drug sales also supporting profits. More: GSK boosts forecast again on back of Shingrix sales Source: News
read more© 1994 - 2024 B.M. Pharmaceuticals